Skip to main content
MedPathMedPath Home
Clinical Trials/JPRN-jRCT2071230090
JPRN-jRCT2071230090
Not yet recruiting
Phase 1

Phase 1, single dose study of M707102 in healthy subjects

ishiura Tomoyuki0 sites16 target enrollmentNovember 19, 2023
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
ishiura Tomoyuki
Enrollment
16
Status
Not yet recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
November 19, 2023
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
Male

Investigators

Sponsor
ishiura Tomoyuki

Eligibility Criteria

Inclusion Criteria

  • •Male subjects from 18 to 49 years of age (at the time of informed consent)

Exclusion Criteria

  • •(1\) Individuals with a history or complications of any of the following diseases
  • •1\)Actinic keratosis, porphyria
  • •2\)Photosensitivity, metabolic diseases such as aminoaciduria, idiopathic or immune diseases such as polymorphic light eruption, genetic diseases such as xeroderma pigmentosum, and diseases for which onset or exacerbation occur due to exposure to sunlight such as systemic lupus erythematosus and pemphigus
  • •(2\) Individuals with a history of allergy or hypersensitivity (including skin hypersensitivity) to any ingredient or metabolite of the investigational medicinal product
  • •(3\) Individuals who are judged to be unsuitable as subject by the principal (sub) investigator

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Phase 2
M201-ASymptomatic Paroxysmal atrial fibrillation
JPRN-jRCT2031190069Kumagai Yuji42
Completed
Phase 1
A Phase 1 study of S-217622COVID-19
JPRN-jRCT2031210202agata Tsutae201
Unknown
Phase 1
A Phase I Single-Dose Study of RO7046015 in Healthy Japanese Me
JPRN-jRCT2080223775CHUGAI PHARMACEUTICAL CO., LTD.24
Active, not recruiting
Not Applicable
Title of the trial for lay people, in easily understood, i.e. non-technical, language: Testing of MZ-004 (investigational product) at different doses in patients who have a completely blocked coronary artery and comparing the results to a placebo or inactive product.The use of MZ-004 to facilitate percutaneous coronary intervention in symptomatic patients with a chronic total occlusion who are indicated for revascularizationTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
EUCTR2014-004649-28-NLMatrizyme Pharma Corporation110
Completed
Phase 2
A 2-stage study to evaluate single doses of MZ-004 at different dose levels in patients with chronic total occlusions. STAGE 1: Open label Training Stage. STAGE 2: Double-blind, randomized, Placebo-Controlled Stage. The TOSCA-5 Study (Total Occlusion Study in Coronary Arteries-5)
NL-OMON41937Matrizyme Pharma Corp.25